Zepbound for Sleep Apnea and Obesity
Managing Obstructive Sleep Apnea with Zepbound
Sleep apnea is a sleep disorder where breathing repeatedly stops and starts. The most common type, obstructive sleep apnea (OSA), occurs when throat muscles relax and block the airway during sleep. Symptoms include loud snoring, episodes of stopped breathing during sleep, gasping for air, and excessive daytime sleepiness. Obesity is a main contributor to OSA.
Zepbound and Sleep Apnea: A Comprehensive Approach
At your initial consult you will meet a licensed medical provider that will evaluate your medical history to see if you are able to be prescribed Zepbound for treatment of your obstructive sleep apnea. Our program includes comprehensive lab review, personalized health evaluations, and continuous support. We aim to empower our patients with the tools and knowledge they need to achieve sustainable health outcomes.
Effective Weight Loss for Better Sleep Health
Recently, the FDA approved Zepbound (tirzepatide) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Tirzepatide, previously approved for obesity and type 2 diabetes under the brand name Mounjaro, works by mimicking hormones that regulate appetite and blood sugar levels3. Clinical trials showed that Zepbound significantly reduced breathing disruptions during sleep and helped with weight loss.